Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2017-10-03 Regulatory Filings
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings
2017-10-03 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes details about the types of securities to be offered (common stock, preferred stock, debt securities, warrants), the maximum aggregate offering price, and other registration details. This is a capital markets filing related to fundraising and securities issuance, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement itself. Therefore, it fits the category of Capital/Financing Update filings.
2017-09-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 14, 2017. It announces preliminary results from a Phase 1 study and mentions a press release and slide presentation attached as exhibits. The document is a regulatory filing to comply with Regulation FD and includes no detailed financial statements or substantive financial data. It primarily serves as an announcement of information and presentation materials rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure.
2017-09-14 English
10-Q
Interim / Quarterly Report Q2 2017
2017-08-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2017, reporting the issuance of a press release announcing second quarter 2017 financial results and a company update. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The length of the document is 3146 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this document is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes such announcements.
2017-08-14 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3), which is a regulatory filing related to securities offerings. It supplements a previously filed prospectus and provides details about the modification of warrant exercise rights and related capital structure changes. The document is relatively short (3605 characters) and focuses on financing terms and securities issuance rather than presenting financial statements or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2017-07-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.